Part:BBa_K5302001
8IIU
This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like.8IIU is an anti-VEGF nanobody, and it has 2 chains, chainA sequence: mdvqlvesgg glvqpggslr lscaasgrtf ssysmgwfrq apgkerefvv aiskggykyd avslegrfti srdnakntvy lqinslrped tavyycassr aygssrlrla dtyeywgqgt lvtvss. chainB sequence:mdvqlvesgg glvqpggslr lscaasgrtf ssysmgwfrq apgkerefvv aiskggyky avslegrfti srdnakntvy lqinslrped tavyycassr aygssrlrla dtyeywgqgt lvtvss. These two chains all show great affinity with VEGF, we used pBBR plasmid as a backbone and transfered 8IIU into Escherichia coli Nissle 1917, and finally succeeded in expressing 8IIU.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
biology | Escherichia coli Nissle 1917 |